Phase 2 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 59 years old (any sex)
- People whose MRI scan shows clear evidence of a brain tumour called glioma
- People whose brain tumour tissue, tested after surgery, has been classified as Grade 4 Glioblastoma according to the 2021 WHO classification system
- People whose post-surgery tumour tissue testing shows a high level of a protein called EGFR (scored as 3 out of 3)
- People with normal blood counts and liver function
- People who fully understand what the trial involves and have signed a consent form
- People who are willing and able to attend appointments, follow the treatment plan, and complete all required study procedures
- People who have no serious illness or injury currently requiring surgery
- People with a normally functioning immune system
Who may not be able to join:
- People with a known allergy to atorvastatin or any of its ingredients
- People currently taking any of the following medications: clarithromycin, itraconazole, ritonavir, saquinavir, lopinavir, cyclosporine, rifampicin, efavirenz, digoxin, warfarin, or oral contraceptives
- People who have another type of cancer (other than glioma), a blood disorder, known failure of multiple organs, or serious conditions such as myasthenia gravis, heart failure, or brain herniation
- People with a history of heart problems, irregular heartbeat, eye disease related to the retina, acute liver porphyria, liver or kidney problems, obesity, uncontrolled diabetes, or other metabolic conditions
- People with abnormal liver function or an active liver disease, including uncontrolled hepatitis
- People with other health conditions that two specialist neurosurgeons determine could interfere with the study
- People who have taken part in another clinical trial within the past 4 weeks
- People who are pregnant or breastfeeding
- People who are unlikely to be able to follow through with the full course of treatment
- People whom the study investigator determines are not suitable for other reasons
- People with a history of HIV, hepatitis B (HBV), or hepatitis C (HCV), or who currently have HIV or HCV
- People with a history of tuberculosis or known active tuberculosis
- People who have had a severe infection, or signs of infection, within 2 weeks before starting the study treatment
- People who have received a live vaccine within 4 weeks before starting the study treatment
- People who have previously had a solid organ transplant or a stem cell transplant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Chunsheng Kang, Tianjin Medical University General Hospital
Phone: +8618622998838
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
progression-free survival; Overall survival; Tumor control rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.